Christoph Steiger

Christoph Steiger has a diverse work experience in the pharmaceutical and academic sectors. From 2019 onwards, they have been working at Bayer, starting as a Lab Head for Drug Delivery Innovation. In this role, they were responsible for building drug delivery technologies for Bayer's novel modality drugs and sourcing/scouting new technologies in this field. Christoph also played a key role in establishing Bayer's non viral vector platform and provided technical and CMC guidance for Bayer's novel modality pipeline. Additionally, they served as a Bayer Science Fellow and currently holds the position of Non Viral Vector Platform Lead.

Before joining Bayer, Christoph held a Feodor Lynen Postdoctoral Fellowship at the Massachusetts Institute of Technology from 2017 to 2019, working under the supervision of Robert Langer.

Christoph Steiger has a diverse education history. Christoph is currently enrolled as a Master of Business Administration (MBA) student at ESMT Berlin, a program they will be completing between 2021 and 2024. Prior to this, they pursued their academic career at The Julius Maximilians University of Würzburg, where they obtained a doctorate (Dr. rer. nat.) in Drug Delivery from 2013 to 2016. In 2012, Steiger attended FAU Erlangen-Nürnberg, focusing on Medicine. Before that, they studied Pharmacy at The Julius Maximilians University of Würzburg from 2009 to 2012.